ZEOX · Zeo ScientifiX, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.”View the 10-Q filed Jun 15, 2026
One customer — 14.2% of revenue (the six months ended April 30, 2026)
“During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 (14.2%) to a large medical practice group and distributor”
One customer — 12.7% of revenue (the six months ended April 30, 2026)
“approximately $511,000 (12.7%) to another large medical practice group and distributor”
One customer — 15.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%) and $228,000 (10.2%) to two individual medical practices”
One customer — 12.1% of revenue (the six months ended April 30, 2025)
“During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor”
One customer — 10.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%) and $228,000 (10.2%) to two individual medical practices”
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Nov 28, 2023; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZEOX
this stock
Zeo ScientifiX, Inc.
|
$10.11M | -53.5% | +12.5% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Nov 28, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZEOX | -19.8% | +8.3% | -34.6% | +8.3% | -53.5% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -20.3% | +5.3% | -48.0% | +5.3% | -66.3% |